Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ENLV | 6-K | bearish | 6/10 | Enlivex announced a cost reduction plan on October 19, 2026, including a ~60% workforce reduction, wind-down of non-clin | Oct 19, 2026 |
| ENLV | PRESS-RELEASE | bearish | 6/10 | Enlivex announced a cost reduction plan to wind down non-clinical R&D, cut workforce by ~60%, and reduce management/CEO | Oct 19, 2026 |
| SLN | DEFA14A | bullish | 8/10 | Silence Therapeutics plc entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, in an all | Oct 19, 2026 |
| FENC | SC 13G/A | bullish | 5/10 | Orin Hirschman and affiliated entities (AIGH Capital Management, AIGH Investment Partners) filed an amended Schedule 13G | Oct 19, 2026 |
| AVBP | 8-K | bullish | 6/10 | ArriVent BioPharma announced the publication of Phase 1b (FURMO-002) results for firmonertinib in EGFR PACC-mutant NSCLC | Oct 19, 2026 |
| SLN | 8-K | bullish | 9/10 | Silence Therapeutics plc has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany in an | Oct 19, 2026 |
| CLNN | 8-K | bullish | 7/10 | Clene Inc. announced it has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval of CNM-Au8 fo | Oct 19, 2026 |
| RDHL | 6-K | neutral | 3/10 | RedHill Biopharma announced a $2.9 million NCI grant to the University of Oklahoma for clinical trials combining opagani | Oct 19, 2026 |
| ACTU | S-1/A | bearish | 7/10 | Actuate Therapeutics filed Pre-Effective Amendment No. 2 to its S-1 registration statement for a public offering of 40,0 | Oct 19, 2026 |
| CRMD | 8-K | bullish | 7/10 | CorMedix announced that the FDA has accepted for filing and granted Priority Review to its supplemental New Drug Applica | Oct 19, 2026 |
| HYPD | PRESS-RELEASE | neutral | 1/10 | Hyperion DeFi, Inc. announced it will host a conference call on November 12 to discuss its Q3 results. | Oct 19, 2026 |
| PHAT | PRESS-RELEASE | neutral | 1/10 | Phathom Pharmaceuticals announced it will report its Q3 2026 results on October 29, 2026. | Oct 19, 2026 |
| URGN | PRESS-RELEASE | bullish | 6/10 | UroGen Pharma announced FDA acceptance of its NDA for UGN-103 (mitomycin) for recurrent low-grade intermediate-risk non- | Oct 19, 2026 |
| BIVI | PRESS-RELEASE | neutral | 5/10 | BioVie presented Phase 2 ADDRESS-LC data for bezisterim in Long COVID at ANA 2026. The trial did not achieve statistical | Oct 19, 2026 |
| CLNN | PRESS-RELEASE | bullish | 8/10 | Clene Inc. announced it has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval of CNM-Au8 fo | Oct 19, 2026 |
| RDHL | PRESS-RELEASE | neutral | 3/10 | RedHill's partner, the University of Oklahoma, received a $2.9 million NCI grant to fund Phase 1b/2 clinical trials of o | Oct 19, 2026 |
| BIIB | PRESS-RELEASE | neutral | 4/10 | Biogen is presenting new 76-week EMPAVELI data at ASN Kidney Week showing sustained proteinuria reduction and continued | Oct 19, 2026 |
| CRMD | PRESS-RELEASE | bullish | 7/10 | CorMedix announced FDA acceptance of its sNDA for REZZAYO (rezafungin) for prophylaxis of invasive fungal disease, with | Oct 19, 2026 |
| BNTX | 6-K | neutral | 4/10 | BioNTech announced it will present 16 abstracts, including a late-breaking oral presentation of first Phase 2 data for p | Oct 19, 2026 |
| GSK | 6-K | bullish | 6/10 | GSK announced first global phase Ib data for its B7-H3-targeted ADC, Ris-Rez, in relapsed extensive-stage small cell lun | Oct 19, 2026 |
| MRKR | 8-K | bullish | 5/10 | Marker Therapeutics announced it was awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials Grants | Oct 19, 2026 |
| IRON | 8-K | bullish | 7/10 | Disc Medicine announced positive topline results from the pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic p | Oct 19, 2026 |
| SMMT | DEF 14A | neutral | 5/10 | Summit Therapeutics is holding a special meeting on November 4, 2026, to approve a charter amendment increasing authoriz | Oct 19, 2026 |
| TNXP | PRESS-RELEASE | neutral | 3/10 | Tonix Pharmaceuticals announced a poster presentation on TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgi | Oct 19, 2026 |
| IRON | PRESS-RELEASE | bullish | 8/10 | Disc Medicine announced overwhelmingly positive topline results from the APOLLO Phase 3 trial of bitopertin in erythropo | Oct 19, 2026 |
| ATYR | PRESS-RELEASE | neutral | 3/10 | aTyr Pharma announced a research collaboration with Albert Einstein College of Medicine to further develop ATYR2810, its | Oct 19, 2026 |
| MRKR | PRESS-RELEASE | bullish | 5/10 | Marker Therapeutics received a $2.6 million FDA Orphan Products Clinical Trials grant to support a Phase 1 study of its | Oct 19, 2026 |
| BNTX | PRESS-RELEASE | neutral | 4/10 | BioNTech announced 16 abstracts across 10 tumor types at ESMO 2026, including first data from the global Phase 2 ROSETTA | Oct 19, 2026 |
| LSTA | DEF 14A | bearish | 7/10 | Lisata Therapeutics is holding a special annual meeting to seek stockholder approval for proposals critical to completin | Oct 19, 2026 |
| AKAN | F-1/A | bearish | 7/10 | Akanda Corp. filed Amendment No. 1 to its F-1 registration statement for a firm-commitment IPO of up to 10,869,565 commo | Oct 19, 2026 |